Hamza Suria
Chief Executive Officer bij Trotana, Inc.
Vermogen: - $ op 31-03-2024
Profiel
Hamza Suria is the CEO of Trotana, Inc. He previously worked as the President, CEO, and Director of AnaptysBio, Inc. from 2011 to 2022.
Prior to that, he held senior positions in business development at Maxygen, Inc., Diabetogen Biosciences, Inc., and Viron Therapeutics, Inc. Suria received his undergraduate degree from Kalamazoo College and attended Mercersburg Academy.
He also received a graduate degree from the University of Western Ontario and an MBA from the Richard Ivey School of Business.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
ANAPTYSBIO, INC.
-.--% | 24-03-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Hamza Suria
Bedrijven | Functie | Begin |
---|---|---|
Trotana, Inc.
Trotana, Inc. BiotechnologyHealth Technology Trotana, Inc. discovers and develops medicines. The company is based in San Diego, CA. The CEO of the company is Hamza Suria. | Chief Executive Officer | - |
Eerdere bekende functies van Hamza Suria
Bedrijven | Functie | Einde |
---|---|---|
ANAPTYSBIO, INC. | Chief Executive Officer | 20-03-2022 |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Corporate Officer/Principal | - |
Diabetogen Biosciences, Inc. | Corporate Officer/Principal | - |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - |
Opleiding van Hamza Suria
Kalamazoo College | Undergraduate Degree |
University of Western Ontario | Graduate Degree |
Mercersburg Academy | Undergraduate Degree |
Richard Ivey School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ANAPTYSBIO, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
Diabetogen Biosciences, Inc. | |
Trotana, Inc.
Trotana, Inc. BiotechnologyHealth Technology Trotana, Inc. discovers and develops medicines. The company is based in San Diego, CA. The CEO of the company is Hamza Suria. | Health Technology |